2019 ASCO Annual Meeting

2019 ASCO Annual Meeting

INTERVIEW WITH SILKE GILLESSEN
Preview of the Advanced Prostate Cancer Consensus Conference 2019 (APCCC)

VIEW ALL ADV PROSTATE VIDEOS

2019 ASCO Annual Meeting

2019 ASCO Annual Meeting

INTERVIEW WITH JONATHAN ROSENBERG
Results from CALGB 90601 in Metastatic Urothelial Carcinoma

VIEW ALL ADV BLADDER VIDEOS

2019 ASCO Annual Meeting

2019 ASCO Annual Meeting

INTERVIEW WITH CORA STERNBERG
SAUL Trial Data: Real World Experience of Atezolizumab in Carcinomas of the Urinary Tract

VIEW ALL UTUC VIDEOS

2019 ASCO Annual Meeting

2019 ASCO Annual Meeting

INTERVIEW WITH TANYA DORFF
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer

VIEW ALL mHSPC VIDEOS

Videos
State-of-the-industry video lectures by leading urology experts
Featured Videos

EAU 2014 - Occult lymph node metastases in patients with muscle invasive bladder cancer: Incidence after neoadjuvant chemotherapy and cystectomy versus cystectomy alone - Session Highlights

STOCKHOLM, SWEDEN (UroToday.com) - Neoadjuvant chemotherapy (NAC) offers a survival benefit to patients with muscle-invasive bladder cancer (MIBC). A pathological complete response is seen in 40% and 10-15% of patients following NAC versus surgery alone, respectively. By contrast, data on the influence of NAC on lymph node involvement and data on the incidence of occult LN metastases after NAC are scarce. Dr. L. S. Mertens and colleagues investigated the influence of NAC on the incidence of LN metastases in clinically node-negative (cN0) patients with MIBC.

eauIncluded in the analysis were 441 patients with cN0M0 MIBC undergoing radical cystectomy (RC) between 1990 and 2012. Eighty-three patients received NAC, and the lymph node templates performed remained the same in both groups during the study period. In patients with cT3-T4 disease, the occurrence of LN metastases was significantly lower in patients treated with NAC (21.9% vs. 40.7%). Following multivariable adjustment for clinical stage, gender, and staging method, receipt of NAC was independently associated with a decreased likelihood of LN metastases (OR 0.41). No significant difference in overall and disease-specific survival was observed between patients treated with or without NAC. However, among those with clinical stage T3-T4 disease, median overall survival was significantly longer in the NAC group (68.0 versus 23.0 months).

NAC appears to be associated with reduced occurrence of occult LN metastases at the time of radical cystectomy. Given the retrospective nature of this study, a prospective study is needed to evaluate whether the effect of NAC on occult LN metastases improves survival.

Presented by L. S. Mertens at the 29th Annual European Association of Urology (EAU) Congress - April 11 - 15, 2014 - Stockholmsmässan - Stockholm, Sweden.

The Netherlands Cancer Institute, Department of Urology, Amsterdam, Netherlands

Written by Jeffrey J. Tomaszewski, MD, medical writer for UroToday.com

 

Conference Coverage
 
Recent data from conferences worldwide
Journals
Publications focusing on urologic cancer treatments through original manuscripts
Everyday Urology Volume 4 Issue 1

Everyday Urology™ - Oncology Insights

PCAN cover

Prostate Cancer and Prostatic Diseases

From the Editor

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe